176 related articles for article (PubMed ID: 22639164)
1. Monoclonal antibody therapy for malignant glioma.
Chen KS; Mitchell DA
Adv Exp Med Biol; 2012; 746():121-41. PubMed ID: 22639164
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhanced delivery in clinical trials.
Hall WA; Rustamzadeh E; Asher AL
Neurosurg Focus; 2003 Feb; 14(2):e2. PubMed ID: 15727423
[TBL] [Abstract][Full Text] [Related]
3. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas.
Vandergrift WA; Patel SJ; Nicholas JS; Varma AK
Neurosurg Focus; 2006 Apr; 20(4):E13. PubMed ID: 16709018
[TBL] [Abstract][Full Text] [Related]
4. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
[TBL] [Abstract][Full Text] [Related]
5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in neuro-oncology.
Stavrou D
Neurosurg Rev; 1990; 13(1):7-18. PubMed ID: 2181345
[TBL] [Abstract][Full Text] [Related]
7. Convection-enhanced delivery: targeted toxin treatment of malignant glioma.
Hall WA; Sherr GT
Neurosurg Focus; 2006 Apr; 20(4):E10. PubMed ID: 16709015
[TBL] [Abstract][Full Text] [Related]
8. Convection-enhanced delivery of targeted toxins for malignant glioma.
Hall WA; Sherr GT
Expert Opin Drug Deliv; 2006 May; 3(3):371-7. PubMed ID: 16640497
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab.
Wu G; Yang W; Barth RF; Kawabata S; Swindall M; Bandyopadhyaya AK; Tjarks W; Khorsandi B; Blue TE; Ferketich AK; Yang M; Christoforidis GA; Sferra TJ; Binns PJ; Riley KJ; Ciesielski MJ; Fenstermaker RA
Clin Cancer Res; 2007 Feb; 13(4):1260-8. PubMed ID: 17317838
[TBL] [Abstract][Full Text] [Related]
10. Clinical studies with targeted toxins in malignant glioma.
Rainov NG; Söling A
Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
[TBL] [Abstract][Full Text] [Related]
12. Emerging monoclonal antibody therapies for malignant gliomas.
Gerber DE; Laterra J
Expert Opin Investig Drugs; 2007 Apr; 16(4):477-94. PubMed ID: 17371196
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
14. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9.
Luther N; Cheung NK; Dunkel IJ; Fraser JF; Edgar MA; Gutin PH; Souweidane MM
Neurosurgery; 2008 Dec; 63(6):1166-74; discussion 1174. PubMed ID: 19057330
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
Sampson JH; Akabani G; Friedman AH; Bigner D; Kunwar S; Berger MS; Bankiewicz KS
Neurosurg Focus; 2006 Apr; 20(4):E14. PubMed ID: 16709019
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive outlook on intracerebral therapy of malignant gliomas.
Buonerba C; Di Lorenzo G; Marinelli A; Federico P; Palmieri G; Imbimbo M; Conti P; Peluso G; De Placido S; Sampson JH
Crit Rev Oncol Hematol; 2011 Oct; 80(1):54-68. PubMed ID: 20888252
[TBL] [Abstract][Full Text] [Related]
17. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
Zhang Y; Sun X; Huang M; Ke Y; Wang J; Liu X
Drug Des Devel Ther; 2015; 9():2947-59. PubMed ID: 26089644
[TBL] [Abstract][Full Text] [Related]
18. Future of convection-enhanced delivery in the treatment of brain tumors.
Bidros DS; Liu JK; Vogelbaum MA
Future Oncol; 2010 Jan; 6(1):117-25. PubMed ID: 20021213
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH
Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045
[TBL] [Abstract][Full Text] [Related]
20. Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.
Hdeib A; Sloan A
Future Oncol; 2012 Jun; 8(6):659-69. PubMed ID: 22764763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
